BioSpace News Archive

In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs. ZS Associates’ Maria Whitman provides analyses and tips.

Centessa Pharmaceuticals plc announced presentation of the first preclinical data for LB101, PD-L1xCD47 LockBody, in a poster presentation at the 2022 American Society of Clinical Oncology Annual Meeting which is taking place virtually and in person from June 3-7, 2022 in Chicago, IL.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, provided an update on 2022 corporate milestones.

Creatv Bio, Division of Creatv MicroTech, Inc., announced the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response of metastatic breast cancer to new lines of therapy following a single cycle of therapy induction.

Amgen and Takeda Pharmaceutical Company announced that new data from the Phase 3 PARADIGM clinical trial of Vectibix® in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer are being featured during the June 5 Plenary Session of the American Society of Clinical Oncology Annual Meeting being held in Chicago and online.

Detailed positive results from the pivotal DESTINY-Breast04 phase 3 trial showed that ENHERTU® demonstrated superior and clinically meaningful progression-free survival and overall survival in previously treated patients with HER2 low 1+ or IHC 2+/in-situ hybridization -negative) unresectable and/or metastatic breast cancer with hormone receptor positive or HR negative disease versus standard of care physician’s choice of chemotherapy.

Eisai announced new investigational data from the platinum-resistant ovarian cancer cohort expansion of a Phase 1 study evaluating the antibody drug conjugate co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin.

Lytix Biopharma AS, a clinical-stage company with an in situ vaccination technology platform, announces data from its ATLAS-IT-04 trial in patients with progressive metastatic soft tissue sarcoma.

eFFECTOR Therapeutics, Inc. reported positive interim results of the company’s ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed treatment was generally well tolerated, resulted in suppression of multiple oncogenic drivers and demonstrated initial signals of clinical activity.

JW Therapeutics presented the latest data of three clinical studies on Carteyva® at the 2022 American Society of Clinical Oncology Annual Meeting/